Taken these together, we have designed a highly sensitive diagnosis kit employing electrochemical methods. We have initially loaded our antibody on an electrode (golden). There is a defined electrical resistance in the absence of pathogenic tau. However, tau-antibody binding would enhance the electrical resistance. The voltage change reflects pathogenic tau concentration in a blood sample.
ALZHEIMER’S DISEASE

DIAGNOSIS KIT

We have previously shown the pathogenic pT231-tau, which is an early driver of tauopathy and neurodegeneration, is having a prion nature and spreads in brain areas as well as CSF and even into the blood. As mentioned earlier, we have now generated a fully human monoclonal antibody (scFv domain) against the pathogenic conformer and have shown that antibody specifically recognizes the pathogenic p-tau species.
ALZHEIMER’S DISEASE

DIAGNOSIS KIT

We have previously shown the pathogenic pT231-tau, which is an early driver of tauopathy and neurodegeneration, is having a prion nature and spreads in brain areas as well as CSF and even into the blood. As mentioned earlier, we have now generated a fully human monoclonal antibody (scFv domain) against the pathogenic conformer and have shown that antibody specifically recognizes the pathogenic p-tau species.
Taken these together, we have designed a highly sensitive diagnosis kit employing electrochemical methods. We have initially loaded our antibody on an electrode (golden). There is a defined electrical resistance in the absence of pathogenic tau. However, tau-antibody binding would enhance the electrical resistance. The voltage change reflects pathogenic tau concentration in a blood sample.


Electron micrograph of the kit surface imaged by SEM. Antibody particles fixed in the golden surface before (left) and after (right) tau binding.


We have shown the kit is very specific to pathogenic tau and also, it may detect tiny p-tau concentrations; up to 10-14 M.

It is notable that p-tau concentration in an AD patient blood sample is around 10-10 M. Thus, our kit is almost 10000 times more sensitive that what it supposed to be and so, we are able to detect p-tau; years ahead of AD clinical manifestation and memory impairment.

Electron micrograph of the kit surface imaged by SEM. Antibody particles fixed in the golden surface before (left) and after (right) tau binding.

We have shown the kit is very specific to pathogenic tau and also, it may detect tiny p-tau concentrations; up to 10-14 M.

It is notable that p-tau concentration in an AD patient blood sample is around 10-10 M. Thus, our kit is almost 10000 times more sensitive that what it supposed to be and so, we are able to detect p-tau; years ahead of AD clinical manifestation and memory impairment.